University of Cambridge begins COVID-19 Clinical Trial Using PharmaJet’s Needle-free System

GOLDEN, Colo. — January 18, 2022 — PharmaJet®, the maker of innovative, needle-free injection technology, today announced that its Needle-free Injection System (NFIS) will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University of Cambridge in the UK, recently announced the start of the Phase 1 clinical trial.